Podcast

February 3, 2019

Podcast: This Week in Managed Care—Congressional Drug Price Hearings and Other Health News

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

Every week, The American Journal of Managed Care^® (AJMC^®) recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

This week, the top managed care news included House and Senate hearings on the cost of prescription drugs; a study finding patients with diabetes can be safely switched to cheaper insulin; and the first non-chemotherapy combination being approved for the treatment of chronic lymphocytic leukemia.

You may need to log in to the website to access this podcast.

Listen above or through one of these podcast services:

Senate Committee Discusses the Burden of High Drug Prices and Potential Solutions

Medicare Patients With Type 2 Diabetes Safely Switched From Analog to Human Insulin, JAMA Study Finds

FDA Approves Ibrutinib Combination as Frontline Treatment for CLL

What Do Americans Think About Medicare for All? It Depends on What They Hear

Congress Doubles Down on High Drug Prices, but Is It More Talk Than Action?

The Drug Price Iceberg: More Than Meets the Eye

Read more about the stories in this podcast:

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos

Marry Vuong, PharmD, BCPPS

Dr Sundar Jagannath

CK Wang, MD, COTA

Eric Lander, MD

Eric Lander, MD

Gordon Crofoot, MD, PA

Related Content

The Legal Architecture of Psychedelic Therapy: Risks, Responsibilities, and Reimbursement Realities

July 30th 2025

The Legal Architecture of Psychedelic Therapy: Risks, Responsibilities, and Reimbursement Realities

Alana Hippensteele, MA

Key legal, ethical, and compliance considerations for managed care professionals navigating the evolving landscape of psychedelic-assisted therapy include regulatory risks, data privacy challenges, reimbursement limitations, and the need for culturally informed care models.

July 24th 2025

High Costs, Coverage Variability Limit Access to Incretin Mimetics for Weight Management

Brooke McCormick Stephen Lott, PharmD, MS Jonathan Gabison, MD, DABOM

This Managed Care Cast episode explores how high costs and inconsistent insurance coverage for incretin mimetics impact obesity management and patient care.

PFAS | Image credit: Vodkaz - stock.adobe.com

July 29th 2025

PFAS Exposure Linked to Increased Risk of Type 2 Diabetes, Study Finds

Elevated levels of per- and polyfluoroalkyl substances (PFAS), also known as “forever chemicals,” may be associated with metabolic disruptions potentially leading to type 2 diabetes.

Managed Care Cast

Published: July 15th 2025 | Updated: July 15th 2025

Navigating Risk, Treatment, and Reimbursement in Precision Oncology: Sadie Dobrozsi, MD

Giuliana Grossi Sadie Dobrozsi, MD, MS Interview by Mary Caffrey

Sadie Dobrozsi, MD, of Evolent, discusses how predictive genomics is pushing cancer care into a new era of personalization

The findings suggest that inhibition of midkine might be a meaningful tool to improve treatment outcomes in SCLC. | Image credit: Pixel-Shot - stock.adobe.com

July 24th 2025

Midkine May Play Key Role in SCLC

Jared Kaltwasser

New data show midkine expression is heightened in small cell lung cancer, suggesting the growth factor may be an important therapeutic target.

The FDA has issued a complete response letter for RP1 plus nivolumab for advanced melanoma after a PD-1 inhibitor–containing regimen. | Image credit: ra2studio - stock.adobe.com

July 24th 2025

RP1 Plus Nivolumab Receives CRL for Advanced Melanoma

The CRL was given because the FDA did not consider the phase 1/2 IGNYTE trial to be an adequate and well-controlled clinical investigation to provide substantial evidence to support approval

Related Content

The Legal Architecture of Psychedelic Therapy: Risks, Responsibilities, and Reimbursement Realities

July 30th 2025

The Legal Architecture of Psychedelic Therapy: Risks, Responsibilities, and Reimbursement Realities

Alana Hippensteele, MA

Key legal, ethical, and compliance considerations for managed care professionals navigating the evolving landscape of psychedelic-assisted therapy include regulatory risks, data privacy challenges, reimbursement limitations, and the need for culturally informed care models.

July 24th 2025

High Costs, Coverage Variability Limit Access to Incretin Mimetics for Weight Management

Brooke McCormick Stephen Lott, PharmD, MS Jonathan Gabison, MD, DABOM

This Managed Care Cast episode explores how high costs and inconsistent insurance coverage for incretin mimetics impact obesity management and patient care.

PFAS | Image credit: Vodkaz - stock.adobe.com

July 29th 2025

PFAS Exposure Linked to Increased Risk of Type 2 Diabetes, Study Finds

Elevated levels of per- and polyfluoroalkyl substances (PFAS), also known as “forever chemicals,” may be associated with metabolic disruptions potentially leading to type 2 diabetes.

Managed Care Cast

Published: July 15th 2025 | Updated: July 15th 2025

Navigating Risk, Treatment, and Reimbursement in Precision Oncology: Sadie Dobrozsi, MD

Giuliana Grossi Sadie Dobrozsi, MD, MS Interview by Mary Caffrey

Sadie Dobrozsi, MD, of Evolent, discusses how predictive genomics is pushing cancer care into a new era of personalization

The findings suggest that inhibition of midkine might be a meaningful tool to improve treatment outcomes in SCLC. | Image credit: Pixel-Shot - stock.adobe.com

July 24th 2025

Midkine May Play Key Role in SCLC

Jared Kaltwasser

New data show midkine expression is heightened in small cell lung cancer, suggesting the growth factor may be an important therapeutic target.

The FDA has issued a complete response letter for RP1 plus nivolumab for advanced melanoma after a PD-1 inhibitor–containing regimen. | Image credit: ra2studio - stock.adobe.com

July 24th 2025

RP1 Plus Nivolumab Receives CRL for Advanced Melanoma

The CRL was given because the FDA did not consider the phase 1/2 IGNYTE trial to be an adequate and well-controlled clinical investigation to provide substantial evidence to support approval

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions